脑癌患者静脉血栓栓塞症的机制与治疗:一篇叙述性综述
本叙述性综述总结了脑癌相关静脉血栓栓塞症(VTE)的发生率、危险因素、病理生理与治疗。胶质母细胞瘤等原发脑癌中肿瘤细胞表达平足蛋白和组织因子是促凝重要驱动因素,且与肿瘤基因谱相关;治疗数据有限且多基于观察性研究,抗凝期间颅内出血风险仍是关键顾虑,回顾性研究提示直接口服抗凝药出血风险可能低于低分子肝素,门诊药物血栓预防不常规推荐。
要点
- 原发和转移性脑癌均与VTE风险显著升高相关,抗凝治疗面临血栓与出血双重风险。
- 原发脑癌(尤其胶质母细胞瘤)肿瘤细胞表达平足蛋白和组织因子是促凝重要病理生理驱动因素,且依赖肿瘤基因谱。
- 脑癌VTE治疗数据有限且多基于观察性研究;回顾性研究提示直接口服抗凝药出血风险可能低于低分子肝素。
核心结论
- 恶性脑肿瘤包括原发性和转移性脑癌均与静脉血栓栓塞症风险显著升高相关。
- 脑癌相关VTE的治疗数据有限且多基于观察性研究,抗凝期间颅内出血仍是关键顾虑。
- 未来需开展研究以改善风险预测、阐明脑癌相关VTE的潜在机制并明确安全有效的治疗策略。
研究设计与样本
- 本文为叙述性综述,纳入并汇总当前关于脑癌相关VTE发生率、危险因素、病理生理和管理的已有知识。
- 综述指出脑癌VTE治疗的临床数据有限,且大多基于观察性研究。
主要发现
- 原发脑癌尤其胶质母细胞瘤中,肿瘤细胞表达促凝蛋白平足蛋白和组织因子被认定为高凝状态的重要病理生理驱动因素。
- 这些促血栓因子的表达被发现依赖于脑肿瘤的基因谱。
- 回顾性研究数据提示,直接口服抗凝药可能与较低出血风险相关,相比低分子肝素。
- 门诊药物血栓预防不常规推荐,主要因该人群缺乏试验数据。
局限性
- 脑癌VTE治疗的临床数据有限,且大多基于观察性研究。
- 门诊药物血栓预防不常规推荐,主要因该人群缺乏试验数据。
- 未来需开展研究以改善风险预测、阐明脑癌相关VTE的潜在机制并明确安全有效的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malignant brain tumors, including both primary brain cancer and metastatic brain cancer, are associated with a markedly increased risk of venous thromboembolism (VTE). Anticoagulation is challenging in this population, as these patients are not only at risk of thrombotic complications but also at high risk of bleeding. In this review, we examine current knowledge on the incidence, risk factors, pathophysiology, and management of brain cancer-associated VTE. In primary brain cancer, particularly in glioblastoma, expression of the procoagulant proteins podoplanin and tissue factor by tumor cells was found to be an important pathophysiological driver of hypercoagulability. Expression of these prothrombotic factors was found to be dependent on the genetic profile of the brain tumor. Clinical data on the treatment of VTE in brain cancer are limited and mostly based on observational studies. The risk of intracranial hemorrhage during anticoagulation remains a key concern. Data from retrospective studies suggest that direct oral anticoagulants may be associated with a lower bleeding risk than low-molecular-weight heparins. Pharmacological thromboprophylaxis in the ambulatory setting is not routinely recommended, largely due to the lack of trial data in this population. Future studies are needed to improve risk prediction, to clarify the underlying mechanisms of brain cancer-associated VTE, and to define safe and effective treatment strategies.
引用
- Hoberstorfer T, Ay C, Riedl J, et al. Mechanisms and treatment of venous thromboembolism in patients with brain cancer: a narrative review. J Thromb Haemost. 2025. PMID: 41187830. doi:10.1016/j.jtha.2025.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。